The emergence of mephedrone and other synthetic cathinones has offered difficulties for lawmakers and regulatory businesses tasked with controlling the proliferation of new psychoactive substances. The dynamic character of synthetic drug generation, coupled with the flexibility of chemists to switch molecular structures to evade lawful limitations,